Literature DB >> 8258230

Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis.

S Wållberg-Jonsson1, G H Dahlén, T K Nilsson, M Rånby, S Rantapää-Dahlqvist.   

Abstract

Tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) and von Willebrand factor (vWF), all of endothelial origin and active in the haemostasis, were analysed in 74 patients with rheumatoid arthritis. The concentrations were related to extra-articular disease and to the incidence of thromboembolic events (TE) registered in a 2-year follow-up period. Patients with extra-articular disease had a significant increase in PAI-1 activity and reduced tPA release in the venous occlusion test. von Willebrand factor, PAI-1 and also haptoglobin and triglycerides were significantly increased in the group of patients who later suffered from TE. In a multiple regression model, in which cholesterol, triglycerides and lipoprotein (a) showed significant association with TE, vWF had the strongest additive explanatory value. No distinct acute phase pattern of PAI-1 was found in any patient subgroup.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8258230     DOI: 10.1007/bf02231572

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  31 in total

Review 1.  Regulation of plasminogen activators and their inhibitors in rheumatic diseases: new understanding and the potential for new directions.

Authors:  D A Hart; M J Fritzler
Journal:  J Rheumatol       Date:  1989-09       Impact factor: 4.666

Review 2.  Lipoprotein (a) in relation to atherosclerotic diseases.

Authors:  G H Dahlén
Journal:  Prog Clin Biol Res       Date:  1988

3.  Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients.

Authors:  P A Reilly; J A Cosh; P J Maddison; J J Rasker; A J Silman
Journal:  Ann Rheum Dis       Date:  1990-06       Impact factor: 19.103

4.  Decreased fibrinolytic activity in juvenile chronic arthritis.

Authors:  L Mussoni; G Pintucci; G Romano; F De Benedetti; M Massa; A Martini
Journal:  Ann Rheum Dis       Date:  1990-12       Impact factor: 19.103

5.  Plasminogen activator in synovial fluid from patients with rheumatoid arthritis.

Authors:  H Kikuchi; S Tanaka; O Matsuo
Journal:  J Rheumatol       Date:  1987-06       Impact factor: 4.666

6.  Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

Authors:  A Hamsten; U de Faire; G Walldius; G Dahlén; A Szamosi; C Landou; M Blombäck; B Wiman
Journal:  Lancet       Date:  1987-07-04       Impact factor: 79.321

7.  The role of antineutrophil cytoplasm antibodies, anticardiolipin antibodies, von Willebrand factor antigen, and fibronectin for the diagnosis of systemic vasculitis.

Authors:  L Bleil; B Manger; T H Winkler; M Herrman; G R Burmester; F E Krapf; J R Kalden
Journal:  J Rheumatol       Date:  1991-08       Impact factor: 4.666

8.  Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor.

Authors:  I M Nilsson; H Ljungnér; L Tengborn
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-18

9.  Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis.

Authors:  S Rantapää-Dahlqvist; S Wållberg-Jonsson; G Dahlén
Journal:  Ann Rheum Dis       Date:  1991-06       Impact factor: 19.103

10.  von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death.

Authors:  J H Jansson; T K Nilsson; O Johnson
Journal:  Br Heart J       Date:  1991-11
View more
  6 in total

1.  Imbalance of tissue-type plasminogen activator (t-PA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity.

Authors:  L T Kopeikina; E F Kamper; V Koutsoukos; Y Bassiakos; I Stavridis
Journal:  Clin Rheumatol       Date:  1997-05       Impact factor: 2.980

2.  Circulating soluble E-selectin in early rheumatoid arthritis: a prospective five year study.

Authors:  A Kuuliala; K Eberhardt; A Takala; H Kautiainen; H Repo; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

Review 3.  Novel risk factors for cardiovascular disease in rheumatoid arthritis.

Authors:  Jenny Amaya-Amaya; Juan Camilo Sarmiento-Monroy; Ruben-Dario Mantilla; Ricardo Pineda-Tamayo; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

4.  Derangement of hemostasis in rheumatoid arthritis: association with demographic, inflammatory and metabolic factors.

Authors:  Theodoros Dimitroulas; Karen M J Douglas; Vasileios F Panoulas; Tracey Toms; Jacqueline P Smith; Gareth J Treharne; Peter Nightingale; James Hodson; George D Kitas
Journal:  Clin Rheumatol       Date:  2013-05-15       Impact factor: 2.980

5.  Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation.

Authors:  Dursun Dursunoğlu; Harun Evrengül; Bülent Polat; Halil Tanriverdi; Veli Cobankara; Asuman Kaftan; Mustafa Kiliç
Journal:  Rheumatol Int       Date:  2004-07-31       Impact factor: 2.631

Review 6.  Cardiovascular involvement in autoimmune diseases.

Authors:  Jenny Amaya-Amaya; Laura Montoya-Sánchez; Adriana Rojas-Villarraga
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.